

Table of Contents

Part I: IMMUNOLOGY AND TARGETING CONSTRUCTS

- 1: The Immune System
- 2: Methods for Development of Monoclonal Antibody Therapeutics
- 3: Peptides
- 4: Affibody Molecules for Targeted Radionuclide Therapy
- 5: Aptamers

Part II: PHYSICS AND RADIOBIOLOGY OF TRT

- 6: The Physics and Radiobiology of TRT
- 7: Chelation Chemistry
- 8: Radiation Dosimetry
- 9: Microdosimetry
- 10: Radiation Safety for RT

Part III: TUMOR MICROENVIRONMENT AND DELIVERY STRATEGIES

- 11: Employing SEREX
- 12: Antibody Penetration into Tumors
- 13: Overcoming Barriers Posed by Solid Tumors
- 14: The Delivery Construct
- 15: The Type of Radionuclide
- 16: Pretargeting Strategies for TRT
- 17: Combined Modality Strategies
- 18: Extracorporeal Techniques
- 19: Concept of Systemic Therapy
- 20: Modeling of the Systemic Cure with TRT

Part IV: UNCONJUGATED THERAPY

- 21: Thyroid Cancer
- 22: Unconjugated Radiopharmaceuticals
- 23: ⁹⁰Y Microspheres
- 24: SIRT

Part V: CONJUGATED THERAPY

- 25: Colorectal Cancer
- 26: Pancreatic Cancer
- 27: Hepatobiliary Cancer
- 28: Astrocytoma

- 29: Medullary Thyroid Cancer
- 30: Head and Neck Cancer
- 31: Prostate Cancer
- 32: Renal Cell Carcinoma
- 33: Bladder Cancer
- 34: Leukemia
- 35: Non-Hodgkin's Lymphoma
- 36: Hodgkin's Disease
- 37: Multiple Myeloma
- 38: Neuroendocrine Tumors
- 39: Malignancies Treated with Peptides
- 40: Ovarian Cancer
- 41: Osteosarcoma
- 42: Pediatric Tumors
- 43: Palliation
- 44: Melanoma